Podcasts about cancer therapies

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.ResourcesCMS: CLFS & PAMA reporting and resourcesPrecision Oncology Therapeutics: Personalized cancer treatmentAnswers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Cancer rates are rising, especially among younger adults and many people are asking deeper questions about prevention, root causes, and what it truly means to heal. In this powerful conversation, we welcome back Dr. Tony Jimenez, founder of Hope for Cancer Treatment Centers, to explore the evolving landscape of integrative cancer care, emotional healing, metabolic health, and proactive prevention strategies. We dive into the connection between chronic stress, unresolved emotional trauma, inflammation, immune dysfunction, metabolic health, and cancer risk, plus practical steps anyone can begin taking today to support longevity and resilience. Dr. Tony also shares fascinating insights into emerging diagnostics, telomere testing, the longevity-associated Klotho gene, hydrogen therapy, detoxification, oxygenation, and why emotional healing may be one of the most overlooked components of wellness. Whether you're navigating a cancer diagnosis, supporting a loved one, or simply wanting to optimize your health proactively, this episode offers hope, empowerment, and actionable insights. In This Episode, we cover: Why cancer rates are increasing in younger populations The connection between chronic stress, emotional trauma, and disease How metabolic dysfunction and insulin resistance impact cancer risk The role of mitochondrial health and inflammation The importance of sleep, hydration, movement, and personalized nutrition Detoxification, immune support, and oxygenation therapies Hydrogen water and hydrogen inhalation therapy explained The emotional component of healing and releasing stored trauma Integrative oncology vs. conventional cancer treatment How to advocate for yourself during a cancer diagnosis Why hope, mindset, and emotional resilience matter in healing Episode Breakdown with Timestamps 00:00 Introduction & the current state of cancer care 06:15 Stress, trauma & lifestyle factors impacting health 19:00 Longevity testing & emerging integrative therapies 33:15 Emotional healing, mindset & resilience 48:00 Integrative oncology & advocating for yourself 1:02:00 Preventing recurrence & creating daily healing habits 1:10:00 Final thoughts on hope & healing Resources & Links Learn more about Hope for Cancer Treatment Centers: hope4cancer Follow Dr. Tony Jimenez and learn about upcoming webinars and wellness programs: https://hope4cancer.com/webinar-replay-all-access/ (Password:  HOPE) Testing we discuss: For Longevity (Klotho Test): https://www.jinfiniti.com/product/agingsos-klotho-test/ For Telomeres: https://repeatdx.com/ Link to the new medical wellness center in Cancun: Sevenby7KP.com   Previous episode: The 7 Key Principles of Cancer Therapy with Dr. Tony Jimenez Sponsor This episode is brought to you by Good Health Saunas, offering commercial grade infrared saunas designed to support detoxification, muscle recovery, relaxation, and better sleep. Visit https://goodhealthsaunas.com or stop by their Mall of America, Appleton, or Waukesha locations. Be sure to mention The Art of Living Well Podcast® for exclusive pricing. Follow and Connect on Instagram: https://www.instagram.com/theartofliving_well Facebook: https://www.facebook.com/theartoflivingwellpodcast/ LinkedIn: https://www.linkedin.com/company/the-art-of-living-well-podcast/?viewAsMember=true Connect with Your Hosts Marnie Dachis Marmet: https://www.instagram.com/zenfullifecoaching Stephanie May Potter: https://www.instagram.com/stephaniemaypotter/

Send us Fan MailFor more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change.Today, we're joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( https://www.amgen.com/ ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients.If you've been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions. That idea is now playing out in the clinic through approaches like bispecific T-cell engagers, which physically link immune cells to cancer cells and force a targeted immune response - offering a new way to go after tumors that have historically been very hard to treat.Dr. Coxon earned her D. Phil in Molecular Biology from the University of Oxford and completed postdoctoral training in vascular biology at Harvard Medical School and Brigham and Women's Hospital. She has built her career at the intersection of cutting-edge biology and strategic drug development, contributing to Amgen's pipeline in areas of significant unmet need, including lung cancer.#SmallCellLungCancer #SCLC #CancerBreakthrough #Immunotherapy #CancerResearch #Biotech #Amgen #DrugDevelopment #Oncology #CancerTreatment #BiTE #BispecificAntibodies #InducedProximity #PrecisionMedicine #ClinicalTrials #MedicalInnovation #FutureOfMedicine #LungCancerAwareness #TranslationalMedicine #Biology #SciencePodcast #HealthcareInnovation #CancerTherapy #Pharma #NextGenMedicineSupport the show

Send us Fan MailSend us Fan MailIn this enlightening episode of Living the Dream with Curveball, we are joined by Bob Ross, a remarkable individual who faced a life-altering brain cancer diagnosis and emerged with profound insights on healing and the mind-body connection. Bob shares his incredible journey, revealing the three critical mistakes people often make when confronting a serious diagnosis, and how he transformed his experience into a mission to help others.With a background in medical physics and a passion for healing, Bob discusses the limitations of traditional cancer therapies and the importance of understanding the root causes of illness. He emphasizes the need for a supportive environment for healing, where the body can thrive rather than merely survive. Bob also introduces his innovative Hidden Secret Brain Technique, designed to help individuals reprogram limiting beliefs and emotional traumas that can hinder recovery.Throughout this episode, listeners will gain valuable insights into the power of belief, the placebo effect, and the role of unresolved emotional trauma in physical health. Bob's inspiring story serves as a testament to the body's innate ability to heal when given the right conditions and mindset. Tune in for a conversation that encourages hope, resilience, and a new perspective on health and healing.What You'll Learn in This Episode:- The three critical mistakes people make when facing a serious diagnosis- How the mind-body connection influences healing- The importance of addressing emotional trauma in the healing process- Insights into Bob's Hidden Secret Brain Technique for reprogramming beliefs- The role of belief and the placebo effect in medical outcomesFor more information on Bob Ross and his work, visit http://TheHiddenSecretToHealing.comSupport the showSupport the show

In this episode of SurgOnc Today, Drs. Kostas Chouliaras and Laura Enomoto recap the highlights from the Advanced Cancer Therapies Meeting in Fort Lauderdale, Florida, with Drs. Michael Lidsky, Jason Foster, and Mecker Moller.

Cancer treatment is rarely about one therapy alone - it requires a strategic, multi-layered approach. In Part 2 of this special two-part episode of Integrative Cancer Solutions, Dr. K continues his conversation with Dr. William LaValley, moving from the science of cancer into the practical side of treatment. This episode focuses on how conventional oncology, repurposed medications, and evidence-based natural therapies can work together to target multiple cancer pathways, improve treatment tolerance, and support long-term outcomes. Dr. LaValley explains how integrative oncology helps weaken cancer's defense mechanisms, improve the effectiveness of chemotherapy and radiation, and address cancer stem cells and tumor signaling that may otherwise remain untouched. If you're looking to better understand how a systems-based treatment strategy can support the body during cancer care, this episode provides an important roadmap. This is Part 2 of 2. Be sure to listen to Part 1 first for the foundational science behind the tumor microenvironment. Key Takeaways: 0:00 Introduction 4:05 Integrative therapies alongside conventional oncology 8:20 Targeting cancer stem cells and recurrence risk 13:40 Supporting chemotherapy and radiation effectiveness 20:10 Personalized protocols and treatment tolerance 28:15 Building the right integrative care team 40:35 How patients can access Dr. LaValley's protocols Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. ____________________________________RESOURCES FROM DR. KARLFELDT:

Emotional pain is not just in your head. It is happening in your body. In this episode of the Nutrition After Breast Cancer: Just the Facts series, we look at the connection between emotional and physical pain through both lived experience and research. When you feel exhausted, overwhelmed, or stuck in a loop of thoughts, there is a biological reason for it. Your nervous system is responding exactly the way it was designed to. But understanding that changes everything. You will walk away with a clearer picture of: Why pain can feel overwhelming and never-ending How your brain processes emotional experiences Why avoidance can quietly shrink your life What it looks like to actually move through pain in a healthy way This is a grounded, honest conversation about what it means to live in a body that has been through something hard and how to care for it moving forward.   Resources Mentioned: Work with Laura: https://www.thebreastcancerrecoverycoach.com/health  Download the app: https://apps.apple.com/us/app/breast-cancer-recovery-coach/id6720763813       REFERENCES Roerink, M.E., van der Schaaf, M.E., et al. (2015). Fatigue in chronic inflammation — a link to pain pathways. Arthritis Research & Therapy, 17(1), 294. Research on central sensitization in chronic pain conditions. On memory, the amygdala, and emotional pain reactivation: Hanson, R. Research on negativity bias and memory encoding. LeDoux, J.E. Research on the amygdala, fear memory, and emotional reactivation. Research on the autobiographical memory system and the persistence of pain (neurocognitive framework for chronic pain). On naming emotion and nervous system regulation: Lieberman, M.D., Eisenberger, N.I., Crockett, M.J., Tom, S.M., Pfeifer, J.H., & Way, B.M. (2007). Putting feelings into words: Affect labeling disrupts amygdala activity in response to affective stimuli. Psychological Science, 18(5), 421–428. On self-compassion and physiological regulation: Neff, K.D. Research on self-compassion, cortisol, and heart rate variability. On psychological and emotional stress as inflammatory drivers: Alschuler, L. Cancer Therapies teachings, Metabolic Terrain Institute of Health.   Let's Connect! If this episode helped you breathe a little easier, please share it with a friend or leave a review. Every share helps spread this message of hope, healing, and whole-person wellness.

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals the company's novel T-cell engager shows complete tumour elimination in mice. Bruno talks to Angus about what T-cell engagers actually are, how AI is driving the company's approach, and why non-intuitive protein design is emerging within immuno-oncology drug development.   You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

In this episode, Pharmacotherapy scientific editor Jim Koeller interviews hematology-oncology specialist Dennis Marjoncu about Dr. Marjoncu's narrative review article “Cancer Therapy-Induced Cardiotoxicity”. They discuss how cardiotoxicity concerns have expanded beyond anthracyclines. They review cardiotoxicity types, monitoring approaches, management principles, drug-interaction considerations, limited prevention data, guideline gaps, and the need for better risk stratification and trial-based cardiac data.

CAR-T cell therapy, a breakthrough treatment that has transformed certain cancer outcomes, is now showing early promise in tackling autoimmune diseases. In a recent case in Germany, a patient with multiple severe autoimmune conditions entered treatment-free remission after receiving the therapy, raising fresh questions about its potential beyond cancer. In this episode, we break down how CAR-T works, why autoimmune diseases are so difficult to treat, and whether this approach could offer long-term remission or even a cure. We also look at the risks, costs and what this could mean for patients in India. Host: Reuben Joe Joseph Guest: Roshan Samuel Mathews, PhD candidate, Albert Einstein College of Medicine, New York Edited and produced by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Sheena: Hi Dr. C! Hope you and your team are well. I'm at 46 yo female in the thick of perimenopause, and suffering from all its symptoms and I also have gut issues too. I'm going to run the Big Five and would also like to run the Menopause and Fertility test as well. My question is, will running the Menopause test be beneficial even though the Big 5 includes the Stress Mood test? I would like as much data as possible because knowledge is power, but also don't want to purchase unnecessary tests. Looking forward for your response!      Anonymous: Have you ever heard of Cantron/Cancel/Protocel? It claims to help with C using bioelectrical wellness. "Stimulate cellular regeneration so body can regenerate/repair more efficiently, by restoring the electrical environment which determines whether cells thrive/die." It has K, NA, Fe, Ca, Cu, sulfur and a blend of phenolic compounds from flavonoid family subgroup catechins, quinones, hydroxyquinones and cyclophentenes. My family knows people that have had success with it. My aunt has triple negative breast cancer despite taking it. She is adiment that she wants to stay on it while working on lifestyle changes. Taking it limits other supplements she can take so I feel stuck in how to help her. Any insight you have would be great!     Alex: Will it boost my metabolism and enable me to enjoy all foods while keeping my weight stable if I do every other day. So one day carbs only next protein only next carbs only next protein only and so on? Thankyou Alex      Anonymous: Is it possible that an inguinal hernia could repair itself without the need for surgery? (Asking for an adult female in case this matters.) What corrective exercises would be recommended, and which exercises should be avoided? How long might this kind of hernia take to repair if it is possible? Thank you!      Patricia: I can't handle any methylated vitamins or quercetin - I react strongly, fatigue, body tingling and aches, migraines. I know the cause - mold, and I'm working on it. However my coach (not an ihp) keeps trying to push methyl's as she says this means I'm methylating poorly. I think this means I can't clear methyl's, not that I don't methylate enough. What do you think? I do have a mthfr variant, not on the primary snp but the other one, and I am a fast COMT. I am trying to figure out how to dial in my b vitamins and how to make sure I don't overdo it. I take all non methyl forms now. This is also keeping me from doing your detox sadly, as the daily nutritional support has methyl's. Any insight or pointers would be appreciated!    Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/3726 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

CardioNerds (Drs. Natalie Marrero, Shivani Reddy, and Rebecca S. Steinberg), discuss the role of SGLT2i in cancer therapy-related cardiac dysfunction (CTRCD) with Dr. Manu Murali Mysore. This episode was produced as part of the CardioNerds Academy curriculum by House Taussig under the guidance of House Chief, Dr. Natalie Marrero, and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Summary: Cancer therapy-related cardiac dysfunction (CTRCD) spans a spectrum from subclinical biomarker elevation to overt heart failure, with risk amplified by preexisting cardiovascular disease, diabetes, hypertension, obesity, and exposure to therapies, such as anthracyclines, HER2-targeted therapies, or radiation. This episode explores the emerging and promising role of SGLT2 inhibitors as a cardioprotective adjunct in cardio-oncology — examining mechanisms, clinical evidence, ongoing trials, and critical knowledge gaps — while affirming that guideline-directed medical therapy remains the cornerstone of prevention and treatment. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls CTRCD is a spectrum — catch it early. CTRCD ranges from subclinical injury detected by imaging and biomarkers to overt heart failure. Early identification in high-risk patients (preexisting CVD, diabetes, HTN, obesity, anthracycline/HER2/radiation exposure) is essential, and early initiation of guideline-directed medical therapy — including ACE inhibitors/ARBs/ARNIs, mineralocorticoid receptor antagonists, and beta-blockers — remains the backbone of prevention and treatment to preserve LVEF and allow safe continuation of cancer therapy. SGLT2 inhibitors are a promising new pillar of cardioprotection in cardio-oncology. They act through a unique combination of mechanisms: renal effects, metabolic reprogramming of the myocardium, anti-inflammatory and antioxidant pathways, and vascular fibrosis modulation — making them a compelling complement to standard therapies rather than a replacement. Early clinical data is encouraging but not yet definitive. The 2024 EMPACARD-PILOT trial demonstrated preserved LVEF and reduced CTRCD in higher-risk patients with diabetes or kidney disease. Ongoing trials — EMPACT and PROTECT — are actively exploring SGLT2 inhibitors for primary prevention during anthracycline and HER2-targeted therapy. SGLT2 inhibitors are NOT yet indicated for ICI-related myocarditis. Immune checkpoint inhibitor (ICI)-related myocarditis is mechanistically immune-driven. While SGLT2 inhibitors have theoretically anti-inflammatory benefits, there is currently no clinical evidence to support their use in this specific setting. The use of SGLT2 inhibitors should be guided by patient risk, existing indications, and ongoing research. Large prospective trials, clarity on timing and patient selection, long-term safety data, and deeper mechanistic understanding in humans remain the most urgent gaps in the field before broader adoption can be recommended. References Theofilis P, Vlachakis PK, Oikonomou E, et al. Cancer therapy-related cardiac dysfunction: A review of current trends in epidemiology, diagnosis, and treatment. Biomedicines. 2024;12(12):2914. doi:10.3390/biomedicines12122914. https://pubmed.ncbi.nlm.nih.gov/39767820/ Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. doi:10.1002/ejhf.1920. https://pmc.ncbi.nlm.nih.gov/articles/PMC8019326/ Li X, Li Y, Zhang T, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151(104577):104577. doi:10.1016/j.phrs.2019.104577. https://pubmed.ncbi.nlm.nih.gov/31790821/ Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors. Nat Rev Endocrinol. 2025;21(12):783-798. doi:10.1038/s41574-025-01170-4. https://pubmed.ncbi.nlm.nih.gov/40935880/ Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6(2):159-182. doi:10.1016/j.jaccao.2024.01.007. https://pubmed.ncbi.nlm.nih.gov/38774006/ Armillotta M, Angeli F, Paolisso P, et al. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. Pharmacol Ther. 2025;270(108861):108861. doi:10.1016/j.pharmthera.2025.10886. https://pubmed.ncbi.nlm.nih.gov/40245989/ Góes-Santos BR, Castro PC, Girardi ACC, Antunes-Correa LM, Davel AP. Vascular effects of SGLT2 inhibitors: evidence and mechanisms. Am J Physiol Cell Physiol. 2025;329(4):C1150-C1160. doi:10.1152/ajpcell.00569.2025. https://pubmed.ncbi.nlm.nih.gov/40908107/ Daniele AJ, Gregorietti V, Costa D, López-Fernández T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial. CardioOncology. 2024;10(1):58. doi:10.1186/s40959-024-00260-y. https://pubmed.ncbi.nlm.nih.gov/39237985/ Clinicaltrials.gov. Clinicaltrials.gov. Accessed April 16, 2026. https://clinicaltrials.gov/study/NCT05271162 Greco A, Quagliariello V, Rizzo G, et al. SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. CardioOncology. 2025;11(1):79. doi:10.1186/s40959-025-00368-9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12400668/ Key Guideline Reference: Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333-e465. doi:10.1093/ehjci/jeac106. https://pubmed.ncbi.nlm.nih.gov/36017575/ Be sure to check out the corresponding review article on the cardioprotective role of SGLT2 inhibitors in CTRCD that will be published in US Cardiology Review, the official journal of CardioNerds. Additionally, please reference CardioNerds Cardio-Oncology Episodes 261 and 274 for related content.

Can functional medicine improve cancer therapy? How can integrative medicine benefit quality of life? What are the most effective integrative modalities?  Dr Wafaa Abdel-Hadi is a Clinical Oncologist and Functional Medicine Doctor, an international Speaker, researcher and the co-founder of AWARE clinic - which guides people on how to take charge of their health through analyzing the pattern of their imbalances and trusting in the Miracle of the human body to heal when given the right tools to survive and thrive, That is called “Reprograming of your body” by implementing the “Recovery Fundamentals”. I had the privilege of seeing Dr Wafaa speaking and Integrative and Personalised Medicine Congress in London where she blew me away with her passionate and enlightening talk on how to improve patient outcomes with integrative. I had the oppurtunity to sit down with her and discuss this fascinating topic in depth. Her compassion and knowledge are palpable.  In this conversation we cover:  Modalities to improve the effectiveness of cancer therapy  The interplay between autoimmunity and cancer  The importance of the tumour micro-environment  The most effective and lost cost integrative therapies And much more Dr Wafer is an advisory board member of the German-based European Keto Live Centre for Ketogenic Metabolic Therapies. She is also on the scientific curriculum board committee of the Integrative Oncology Working Group, USA and the first certified Functional Medicine Doctor in Egypt and the Middle East. SOCIALS https://drwafaafxmed.com/ https://x.com/drwafaafxmed https://www.instagram.com/drwafaafxmed/

In this episode of the Treating Together podcast, host Dr Pallav Mehta, medical oncologist at MD Anderson Cancer Center at Cooper, assistant professor of medicine at Cooper Medical School, and medical director of Reimagine Care,sits down with Jorge Garcia, PharmD, founder of Patagonia Healthcare, for an in-depth conversation about the rapidly evolving landscape of advanced cancer therapies, from CAR-T cells and bispecific antibodies to gene therapies.Together, they explore what makes these treatments fundamentally different from traditional chemotherapy and immunotherapy, and why the systems built to deliver them must evolve just as quickly. The discussion covers the operational, financial, and clinical challenges facing health systems looking to bring bispecific therapies into community and outpatient settings — including reimbursement models, toxicity monitoring, caregiver education, and the critical role of oncology pharmacists. Dr Mehta and Dr Garcia also look ahead to the growing promise of technology, AI, and virtual care in enabling safer patient monitoring outside of hospital walls, and share their vision for a future where more patients can receive these transformative treatments closer to home.Whether you're a clinician, administrator, pharmacist, or healthcare innovator, this conversation offers a grounded and forward-looking perspective on what it will take to make cutting-edge cancer care accessible to all patients—not just those near major academic centers.

Send a textIn this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Stephanie Culler, co-founder and CEO of Persephone Biosciences, to explore one of the most rapidly evolving frontiers in modern health science: the human microbiome. From early immune development to cancer therapy, the conversation reveals how the trillions of microbes living in our bodies may shape health in ways scientists are only beginning to understand.Dr. Culler's path into microbiome research began with a personal mission to understand disease after losing both of her grandmothers to cancer. Following her PhD at the California Institute of Technology, where she studied gene therapy approaches to cancer, she moved into industrial biotechnology and microbial engineering. That work eventually led her to co-found Persephone Biosciences, a company focused on translating microbiome science into real-world therapeutics and consumer health solutions.A major focus of the discussion centers on the infant microbiome and its role in shaping immune development. Dr. Culler explains how microbes transferred during birth and nourished through breast milk help “train” the immune system in the earliest stages of life. Yet modern research suggests that key beneficial bacteria—particularly Bifidobacterium infantis—have dramatically declined in Western infants. In large-scale studies conducted by Persephone, only a small percentage of U.S. infants carry adequate levels of this once-dominant microbe.The conversation also explores how microbiome balance may influence responses to cutting-edge cancer treatments like immunotherapy. Emerging research suggests that gut bacteria can significantly affect how patients respond to checkpoint inhibitors, opening the door to microbiome-based interventions that could enhance treatment outcomes.Listen to the full episode to hear Dr. Stephanie Culler explain how microbiome science is transforming our understanding of immunity, disease prevention, and the future of medicine.Learn more about Persephone BiosciencesDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

What if a drug could kill cancer cells broadly, spare the immune system and then train it to keep fighting, without triggering resistance? That's the promise behind the ELANE pathway, a mechanism discovered not from a hypothesis but from studying fundamental biology in patients. In this episode of the In Vivo Podcast, Court Turner, CEO and co-founder of Onchilles Pharma, and Lev Becker, CSO and scientific founder, discuss how a neutrophil elastase-based mechanism is being translated into N17350, a first-in-class intratumoral agent targeting solid tumours including head and neck, skin and breast cancers. With $40m raised, GMP manufacturing of thousands of clinical doses completed, a US IND approved, and a first-in-human study underway in Australia, Onchilles is moving from "stubborn optimism" to clinical execution. Court and Lev discuss the dual mechanism that sets N17350 apart from both traditional chemotherapy and immunotherapy, why histone H1 functions as a universal tumour vulnerability rather than a conventional biomarker, and how they're thinking about combinations, partnering and the eventual value story for payers.

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to provide additional details from the company's Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of Basal Cell Carcinoma. The data showed the strongest treatment response in the 200-microgram cohort, which achieved 73% clinical clearance and 40% histological clearance at Day 57. The results highlight the therapeutic potential of the company's SkinJect platform, which uses microneedle technology to deliver chemotherapy directly into skin lesions without surgery. According to Medicus Pharma, the findings are particularly notable given the device-based mechanism of SkinJect. The microneedle delivery process itself may produce biological activity, which can contribute to responses even in the placebo arm of the trial. In this study, the placebo microneedle array (P-MNA) was not tip-loaded with the chemotherapeutic agent but could still stimulate a biological response due to the mechanical action of the device. The company noted that active placebo arms are not uncommon in device-drug combination trials and can be considered an acceptable regulatory data point. Importantly, the results demonstrated a clear separation in treatment response between the D-MNA therapy arm and the placebo microneedle arm in the 200-µg cohort, with clinical clearance rates of 73% and 38% respectively. Management believes the dataset represents decision-grade evidence supporting the continued advancement of the SkinJect program as a potential non-surgical treatment option for patients with basal cell carcinoma. The company plans to move forward with an End-of-Phase-2 meeting with the U.S. Food and Drug Administration to determine the optimal registrational development pathway and explore. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma #SkinJect #Biotech

Coming up, we explore how CAR-T cell therapy is revolutionising personalised cancer treatment. Plus, how NASA's DART mission tested Earth's asteroid defence, what we are learning about the benefits of breastfeeding for mother and baby health, and we delve into the physics behind squeaky shoes... Like this podcast? Please help us by supporting the Naked Scientists

Host: Darryl S. Chutka, M.D.  Guest: Balaji Tamarappoo, M.D., Ph.D.  With advances in oncology, patients are living longer than ever following a diagnosis of cancer. Newer treatments have dramatically improved survival. However, we're also seeing an increasing number of cancer survivors who are at risk for cardiovascular complications; at times during treatment, and sometimes years later. Complications such as heart failure, cardiac arrhythmias, hypertension, and accelerated coronary disease are not uncommonly seen in our primary care practice.  As primary care clinicians, what do we need to know? I'm joined today by Dr. Balaji Tamarappoo, M.D., Ph.D., a cardiologist with expertise in cardio-oncology. We'll discuss which cancer therapies pose the highest cardiac risks, what baseline and surveillance testing is recommended, if the risk of cardiotoxicity be decreased, and how primary care can partner effectively with oncology and cardiology to protect our patients' hearts while they battle their malignancy. The topic for today's podcast is “Cardiotoxicity of Cancer Therapies.”  Mayo Clinic Talks: Heart Health | Mayo Clinic School of Continuous Professional Development  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

This week Bobbi Conner talks with MUSC's Dr. Besim Ogretmen about research exploring new cancer therapies.

Exploring a Novel Nutraceutical Approach to Brain Cancer Treatment: Nutritionist Leyla Muedin discusses a recent study from the Advanced Center for Treatment, Research, and Education in Cancer in Mumbai, India. The study explores the impact of a simple, cost-effective nutraceutical tablet containing resveratrol and copper on glioblastoma, a highly aggressive brain cancer. The results indicate a favorable shift in cancer markers and a reduction in tumor aggression without the side effects associated with conventional treatments like chemotherapy and radiotherapy. This alternative approach suggests a potential paradigm shift in cancer treatment, focusing on healing rather than destroying cancer cells. The episode highlights the significance of thinking outside traditional cancer treatment methods and the promise of nutraceuticals in oncology.

What if the most powerful cancer treatments already exist — but aren't being offered because they fall outside the guidelines?In this episode of Integrative Cancer Solutions, Dr. Michael Karlfeldt sits down with world-renowned interventional radiologist and oncology innovator Dr. Syed Hasnain Haider-Shah to explore why modern cancer care often prioritizes protocols over patients. From catheter-directed chemotherapy and tumor embolization to immune-based strategies, photobiomodulation, and precision nutrition, Dr. Shah reveals how advanced cancer treatments are being used globally — especially in China — while remaining largely inaccessible in the U.S.This conversation dives deep into the limitations of chemotherapy and radiation, the intelligence of cancer stem cells, immune system suppression, cancer cachexia, and why integrative, individualized approaches give patients their best chance at long-term survival. If you or someone you love is navigating a cancer diagnosis and searching for real options beyond “standard of care,” this episode is essential listening.Key Takeaways:5:20 Radiation therapy risks and how to support recovery nutritionally11:46 Why systemic chemotherapy often fails and selects for aggressive cancer cells12:17 Catheter-directed chemotherapy: targeting tumors without poisoning the body16:25 The immune system as the most powerful anti-cancer weapon26:37 Tumor embolization: starving cancer by cutting off its blood supply34:50 Why advanced cancer therapies thrive in China but are restricted in the U.S.Resources Mentioned:Williams Cancer Institute (Mexico) – https://williamscancerinstitute.comPhotobiomodulation / Intravenous Light Therapy (General Overview) – https://pubmed.ncbi.nlm.nih.gov Want to guest on our shows?Calendly Link for Integrative Lyme Solutions: https://calendly.com/drmichaelk/integrative-lyme-solutions-podcast-interviewCalendly Link for Integrative Cancer Solutions: https://calendly.com/drmichaelk/podcast-interviewCalendly Link for Dr. K Show: https://calendly.com/drmichaelk/dr-k-show-interview Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery-URL: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lyme-Price: $24.99-Discount Code: LYMEPODCASTUnleashing 10X Power: A Revolutionary Approach to Conquering Cancer-URL: https://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancer-URL: https://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-Discount Code: CANCERPODCAST2The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and Purpose-URL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-Discount Code: DRKSHOWPODCAST -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of remarkable advancements and strategic collaborations in the industry, showcasing a dynamic period of innovation and regulatory evolution.Corcept Therapeutics has celebrated a significant win with their Phase 3 trial for relacorilant targeting ovarian cancer, revealing improved overall survival rates. This marks a potential rebound for Corcept following a previous FDA rejection for Cushing's syndrome, setting the stage for an impactful new cancer therapy. The success of this trial underscores the critical importance of positive clinical outcomes in securing regulatory approvals and preparing for market entry.Bristol Myers Squibb has embarked on an ambitious $850 million partnership with Janux Therapeutics to develop a novel tumor-activated therapeutic using T-cell engager technology. This collaboration is part of an ongoing trend towards personalized medicine and immunotherapy, where targeted treatments are preferred for their specificity and reduced systemic toxicity. Such partnerships not only combine resources but also accelerate the development of innovative cancer treatments.Corxel Pharmaceuticals has secured $287 million in Series D funding to advance its oral GLP-1 receptor agonist through Phase 2/3 trials addressing obesity. This significant investment highlights the growing interest in treatments for metabolic disorders, particularly as obesity remains a global health challenge with substantial unmet needs. Oral GLP-1 therapies offer promise given their potential for improved patient compliance compared to injectable forms.The regulatory landscape is also evolving. The FDA has issued draft guidance on utilizing minimal residual disease (MRD) and complete response metrics to support accelerated drug approvals for multiple myeloma treatments. This reflects an adaptive approach aimed at expediting access to life-saving therapies by leveraging advanced biomarkers and response measures. It also signifies a shift towards precision medicine, where treatment efficacy is closely monitored through molecular markers.Hoth Therapeutics has reported promising Phase 2 results addressing skin toxicities caused by EGFR inhibitors, common adverse effects in cancer treatment regimens. Despite this progress in supportive oncology care, Hoth's share price has remained stagnant, potentially due to market skepticism or the need for more data to substantiate clinical benefits.The industry continues to attract significant venture capital, as evidenced by companies like Mendra launching with $82 million to focus on innovative biotech solutions. These financial infusions are crucial for advancing early-stage research into clinical applications.On the legal front, Johnson & Johnson faces challenges with ongoing talc litigation. A court-appointed official has recommended allowing expert testimony on scientific evidence linking talc products to cancer. This could impact J&J's defense strategy and underscores the importance of robust scientific validation in legal contexts.Overall, these developments reflect an industry characterized by robust innovation, strategic collaborations, and evolving regulatory frameworks. The focus on targeted therapies, personalized medicine, and accelerated approval processes underscores a commitment to addressing complex health challenges while enhancing patient care outcomes.Shifting our attention to global trends, Samsung Biologics has achieved a financial milestone by becoming the first Korean biopharmaceutical company to exceed an annual profit of 2 trillion won ($1.4 billion). This accomplishment underscores the company's robust growth trajectory and strategic positioning in the global biopharma landscape, reflecting broader trends where increased demand for biologics and bioSupport the show

Dr. Nathan Goodyear is a Board-Certified OB/GYN and a leading expert in integrative oncology with nearly two decades of experience blending conventional and holistic cancer therapies. He has served as medical director for multiple integrative cancer clinics, authored three books, including Breaking the Cancer Code, and is a sought-after speaker and podcaster on innovative treatments such as high-dose IV vitamin C, Precision Therapy Stacking, and Low-Dose Metronomic Chemotherapy. Dr. Goodyear is dedicated to empowering both patients and physicians through education, advocacy, and cutting-edge care.   Key Takeaways To Tune In For: (03:49) – The War on Cancer: A Flawed Approach (09:56) – New Cancer Types and Immune Dysfunction (22:07) – Innovative and Targeted Treatments (29:56) – Remarkable Patient Outcomes (35:19) – Beyond Traditional Cancer Treatment (43:00) – Advocacy, Ethics, and the Future of Medicine   Resources talked about in this episode: Website:  Dr. Goodyear Pre-scribed  Off-Script Williams Cancer Institute Social media handles: IG: Dr Goodyear, Off script, Williams Cancer Institute FB: Dr. Goodyear, Pre-scribed, Off script Rx

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, interviews Dr. Brent Sear, director of the Clinical Pharmacology Shared Resource at KU Cancer Center. Brent shares his unique career journey into clinical pharmacology, the role of clinical pharmacology in advancing cancer therapies, and the critical work his team does in guiding clinical trials and personalizing cancer treatment. They also discuss emerging technologies and their potential impact on the future of cancer research. Tune in to learn more about the intricate processes that ensure safe and effective cancer therapies. 00:00 Introduction to the Podcast and Guest 01:06 Brent Sear's Journey into Cancer Research 03:21 Understanding Clinical Pharmacology 04:54 The Role of Clinical Pharmacology Shared Resource 06:40 Importance of Precise Measurement in Cancer Treatment 08:40 Collaborative Projects and Scientific Insights 09:55 Advice for Aspiring Researchers 11:52 Future of Clinical Pharmacology in Cancer Research 13:33 Conclusion and Farewell Links from this Episode: ·       Learn more about the Clinical Pharmacology Shared Resource at KU Cancer Center ·       Learn about Brent Sear, director of the Clinical Pharmacology Shared Resource ·       Learn about Shared Resources and Core Facilities at KU Cancer Center To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

After 20+ years treating cancer patients, Dr. Christy Kesslering started asking a question her colleagues weren't asking: why are so many of my breast cancer patients metabolically sick — even when they're not obese?That question changed everything.Dr. Kesslering is a classically-trained radiation oncologist, metabolic health practitioner, and terrain theorist. She spent two decades practicing oncology in the Chicagoland area before transitioning to focus full-time on what she believes is the missing piece in cancer care: mitochondrial health, and metabolic dysfunction. She now works with cancer patients and chronic disease clients through a telehealth practice built on comprehensive lab work, real-food nutrition, and terrain-based principles.Questions Answered in This Episode:What is mitochondrial dysfunction and how does it relate to cancer?Are processed foods, seed oils, and glyphosate implicated in rising cancer rates?Can fasting or ketogenic diets reduce chemotherapy side effects?What's the difference between cachexia and healthy fat loss in cancer patients?How do you identify which foods are problematic for your body specifically?What does Dr. Kesslering believe has the biggest impact on cancer outcomes?A rare look at what happens when a passionate physician follows the data wherever it leads — and why she believes the future of cancer care starts with metabolism.Big thanks to our sponsors:✅Genova Connect – Get 15% off any test kit with code METABOLICLINK here!✅ Fatty15 – Get 15% off a 90-day Starter Kit with code METABOLICLINK here.✅ ZocDoc - Find and instantly book a top-rated doctor here.In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Commentary by Dr. Peter van der Meer.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

In today's episode, we are joined by Professor Stephen Maher, an expert in translational oncology and radiation research at Trinity College Dublin, where he also serves as the Director of Postgraduate Studies for the School of Medicine. Stephen's work focuses on understanding why some cancers respond to treatment while others resist it — particularly in relation to chemotherapy and radiotherapy. His research explores how factors like microRNAs, the DNA damage response, and tumor hypoxia influence treatment sensitivity, with a strong emphasis on oesophageal and pancreatic cancers. Hit play to explore: The future of anti-cancer therapeutics. The ways that radiation research is evolving. Why translational oncology is so important for improving patient outcomes. After completing his Ph.D. in Oncology at RCSI and a fellowship at the National Cancer Institute in Maryland, Stephen has built a career dedicated to bridging lab-based discovery with patient-focused care. He leads national and international collaborations in cancer biology and has helped develop cutting-edge radiotherapy and hypoxia research cores at Trinity's Translational Medicine Institute. Click here to learn more about Stephen and his important work!

What if the cancer treatment that works best is the one pharmaceutical companies can't profit from? What if one of the cancer treatments that works best is the one the pharmaceutical companies can't profit from?!Dr. Katie sits down again with Professor Thomas Seyfried to explore why the medical system resists alternative approaches to a disease that claims over 1,700 lives daily in the U.S., and what's actually driving cancer at the cellular level. They reveal a specific therapeutic strategy that targets both fuels cancer cells depend on to survive.Dr. Seyfried explains how cancer isn't the genetic lottery you've been led to believe, it's a metabolic condition with a metabolic solution. You'll learn why your body's normal cells thrive on completely different fuel than cancer cells do, and how a compound called DON (a glutamine antagonist) combined with therapeutic ketosis creates conditions where healthy cells flourish while cancer cells can't survive. Chapters:00:13:25 – Starving the Tumor00:16:22 – The Banned Cancer Drug00:21:03 – Beyond the Keto Diet00:32:00 – Why Healing Threatens the ‘System'00:37:15 – The Genetic MythDr. Katie and Dr. Seyfried discuss the practical challenges patients face when trying to find providers who understand this science, why measuring your glucose-ketone index matters more than following any specific meal plan.Dr. Seyfried's research team is seeing remarkable outcomes in advanced cases that conventional medicine has given up on, and he shares exactly what that approach looks like.Listen and learn why the paradigm shift in cancer management isn't just coming, it's already here, waiting for the rest of the world to catch up.Dr. Seyfried: https://www.bc.edu/bc-web/schools/morrissey/departments/biology/people/faculty-directory/thomas-seyfried.htmlAccess the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

In this episode, we talk with Dr. Sharon about the complex intersection of oncology and autoimmunity through the lens of immune checkpoint inhibitors (ICIs)—therapies that have transformed cancer care but can also unleash immune-related adverse events (irAEs). Dr. Elad explains how ICIs work, why they can trigger autoimmune-like toxicities, and what distinguishes rheumatologic irAEs from classic autoimmune diseases. We explore the mechanistic overlaps between cancer immunotherapy and autoimmunity, the ethical and clinical dilemmas of balancing immune suppression with cancer control, and emerging biomarkers that may predict risk. Dr. Sharon also reflects on his career journey—from leading drug development efforts at the National Cancer Institute to returning to academia—and shares insights on collaboration, innovation, and the evolving partnership between oncologists and rheumatologists in managing these challenging conditions. 

Dr. Bahar Mansoori explores how musculoskeletal complications from radiation therapy and immunotherapy can mimic metastatic disease and pose diagnostic challenges. She discusses key imaging patterns, pitfalls, and strategies radiologists can use to improve accuracy and patient care.   Musculoskeletal Complications of RadiationTherapy and Immunotherapy. Azhideh and Haseli et al. RadioGraphics 2025; 45(10):e250014. 

Although initial clinical trials of tamoxifen as a treatment of breast cancer were positive, Imperial Chemical Industries (ICI) did not believe this market would be commercially viable. The company had hoped for a contraceptive pill – tamoxifen didn't work for that – not a cancer treatment. In 1972 the higher-ups at ICI decided to cancel the research.‍But Dora Richardson, the chemist who had originally synthesized the compound, and her boss, Arthur Walpole, were convinced they were on to something important, something that could save lives. They continued the research in secret. Tamoxifen was eventually launched in 1973 and went on to become a global success, saving hundreds of thousands of lives. Dora Richardson's role in its development, however, was overshadowed by her a male colleague and all but forgotten.This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

In the early 1960s, Dr. Dora Richardson synthesized a chemical compound that became one of the most important drugs to treat breast cancer: tamoxifen. Although her name is on the original patent, her contributions have been lost to history.In the first episode of this two-part podcast, Katie Couric introduces us to Dora's story, and we show how Lost Women of Science producer Marcy Thompson tracked down Dora's firsthand account of the history of the drug's development. This document, lost for decades, tells the story of how the compound was made and how Imperial Chemical Industries, where Richardson worked, almost terminated the project because the company was hoping to produce a contraceptive, not a cancer therapy.This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

Featuring an interview with Dr Neel Pasricha, including the following topics: Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00) Association of corneal toxicities with ADCs (4:56) Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02) Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44) Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55) Other ocular toxicities associated with cancer therapies (24:26) Prevention and management of corneal toxicity (33:58) Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39) General clinical pearls on the management of ocular toxicities with cancer therapies (48:04) CME information and select publications

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.

Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics:  Introduction: The Patient Experience (0:00) Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28) Ocular Toxicities in Multiple Myeloma (45:33) Ocular Toxicities in Breast Cancer (50:34) CME information and select publications

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.

This week on our Live Show we discussed Trump Tarriffs illegal, Nato fotress in Romania, arson firefighter, ebbing asylum hotel, health and more   Donations https://www.awakeningpodcast.org/support/   #awakening #brainfitness #Romania   About my Co-Host: Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation).   What we Discussed:   00:26 What the Picture on our Introduction Means   01:15 What we will be discussing in this weeks Show 03:00 LeeuWarden Update 05:20 Why Courts Can Not be Trusted 06:30 How you can Help the Podcast 07:25 Trumps Tariffs are Illegal 10:10 Is the US a Dictatorship 12:20 NATO Building its Largest Military Base in Romania    14:30 Arsonist was a Firefighter 17:24 Shariah law recognised in Austria 19:12 The dangers of the Burka 20:05 Epping Asylum Hotel Cout Case Overturned 25:20 Are You Working on Brain Fitness 26:45 Google New Phone Pixel 10 30:40 Googles Jules 2.0 32:30 ChatGpt Court case for causing Suicide 36:40 Denmark make your Face and Voice as your IP 39:17 How a Virtual Assistant Can Help your Business 40:00 Cancer Therapy for Cat might help Humans 41:25 From Fishing and Oil Disaster to Farming 43:50 Spirecord Repair 46:00 Universal Health Trackers 48:05 The dangers of Devices that use WiFi 48:45 Organipeel has been discontinued 51:25 More than 2 Billion lack access to Safe Drinking Water 56:35 Pure Human by Greg Braden 58:00 Mecico's Massive Poverty Reduction 1:00:40 Flight Pattern of Birds   How to Contact Arnold Beekes:   https://braingym.fitness/   https://www.linkedin.com/in/arnoldbeekes/   Donations ⁠⁠ https://www.awakeningpodcast.org/support/   https://www.podpage.com/speaking-podcast/support/ ⁠⁠   All about Roy / Brain Gym & Virtual Assistants at https://roycoughlan.com/  

This week on our Live Show we discussed Trump Tarriffs illegal, Nato fotress in Romania, arson firefighter, ebbing asylum hotel, health and more Donations https://www.awakeningpodcast.org/support/ #awakening #brainfitness #Romania About my Co-Host:Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation). What we Discussed: 00:26 What the Picture on our Introduction Means 01:15 What we will be discussing in this weeks Show03:00 LeeuWarden Update05:20 Why Courts Can Not be Trusted06:30 How you can Help the Podcast07:25 Trumps Tariffs are Illegal10:10 Is the US a Dictatorship12:20 NATO Building its Largest Military Base in Romania  14:30 Arsonist was a Firefighter17:24 Shariah law recognised in Austria19:12 The dangers of the Burka20:05 Epping Asylum Hotel Cout Case Overturned25:20 Are You Working on Brain Fitness26:45 Google New Phone Pixel 1030:40 Googles Jules 2.032:30 ChatGpt Court case for causing Suicide36:40 Denmark make your Face and Voice as your IP39:17 How a Virtual Assistant Can Help your Business40:00 Cancer Therapy for Cat might help Humans41:25 From Fishing and Oil Disaster to Farming43:50 Spirecord Repair46:00 Universal Health Trackers48:05 The dangers of Devices that use WiFi48:45 Organipeel has been discontinued51:25 More than 2 Billion lack access to Safe Drinking Water56:35 Pure Human by Greg Braden58:00 Mecico's Massive Poverty Reduction1:00:40 Flight Pattern of Birds How to Contact Arnold Beekes: https://braingym.fitness/ https://www.linkedin.com/in/arnoldbeekes/ Donations ⁠⁠ https://www.awakeningpodcast.org/support/ https://www.podpage.com/speaking-podcast/support/ ⁠⁠ All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/ 

Could cancer treatment be approached in a way that restores the body instead of breaking it down? In this powerful conversation, Dr. Hotze sits down with Dr. Nathan Goodyear, a leader in integrative oncology, to discuss how addressing the root causes of cancer can help patients achieve better health outcomes and an improved quality of life. Dr. Goodyear explains how his approach focuses on supporting the immune system, reducing inflammation, and using natural, targeted therapies that work with the body's healing processes. They explore how factors like the immune system, nutrition, toxins, tubal ligation, hysterectomy, mitochondria, and hormone imbalances play a role in overall impacts on your health, unnecessary symptoms, and even the potential development of cancer, and how restoring balance can help assist the body's ability to fight back in resolving symptoms and illnesses. If you or someone you love is facing cancer, this episode will open your eyes to treatment strategies that prioritize health, wellness, and quality of life over the one-size-fits-all approach of conventional medicine. For more information about Dr. Goodyear and other resources discussed today, please visit the following.   @ Dr.Goodyear (Instagram) https://www.instagram.com/dr.goodyear/?hl=en Website URLs: https://williamscancerinstitute.com/ https://pre-scribed.com/ https://www.off-scriptrx.com/ https://www.docgoodyear.com/ https://metabolicregen.com/   Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

- Green Tea and Cognitive Benefits (0:10) - Critique of Pharmaceuticals and Big Pharma (2:39) - Green Tea and Brain Health (4:31) - Speed Cubing and Cognitive Training (10:47) - Green Tea and Cancer Prevention (15:59) - Green Tea and Heavy Metal Detoxification (24:45) - L-Theanine and Anxiety Relief (30:04) - Catechins and Polyphenols in Green Tea (36:21) - Green Tea Extracts and Supplements (39:14) - Green Tea and Cancer Therapy (50:57) - Colloidal Silver and Its Benefits (1:11:38) - Silver Nanoparticles and Cancer Research (1:23:02) - Historical and Metaphysical Significance of Metals (1:26:08) - Economic and Political Implications of Metals (1:27:53) - Challenges and Opportunities in Health and Science (1:30:08) - Personal Reflections and Future Plans (1:37:17) - Final Thoughts and Gratitude (1:41:15) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Episode Summary: Why is cancer on the rise—especially among younger generations?  In this powerful episode of The Art of Living Well Podcast, we sit down with Dr. Tony Jimenez to discuss the root causes of cancer, the role of integrative oncology, and his seven key principles for cancer therapy. Dr. Tony shares his personal journey into holistic cancer care, highlighting the importance of nutrition, detoxification, immune support, and emotional healing.  He also breaks down non-toxic treatments, the significance of dental health, and why practices like coffee enemas and oxygenation can make a profound impact on overall wellness. If you're looking to take proactive steps toward cancer prevention, boost your health, and gain insights into holistic healing, this episode is a must-listen!   Key Takeaways: ✅ Toxicity & lifestyle choices play a major role in cancer development  ✅ A personalized approach to nutrition is key to healing & longevity  ✅ Detoxification & immune system support are crucial for disease prevention  ✅ Coffee enemas can enhance cognitive function & boost glutathione levels  ✅ Oxygenation is essential for overall health—and it's free!  ✅ Your oral microbiome & dental health directly impact your body's wellness  ✅ Emotional healing & trauma work are vital for long-term health Tune in now to learn how you can take charge of your health and longevity! Chapters 08:26 Understanding Cancer: Causes and Growth 19:47 Trends in Cancer: What We're Seeing Today 20:16 The Seven Key Principles of Cancer Therapy 34:05 The Power of Coffee Enemas 38:38 Understanding the Microbiome 41:27 Dental Health and Toxicity 53:00 The Emotional Component of Healing 01:00:10 Practical Steps for Longevity We'd love to hear your thoughts! Connect with us on social media or email us at theartoflivingwellpodcast@gmail.com

Cancer rates are at an all-time high...     And while conventional treatments continue to advance, there are natural therapies being widely used in other parts of the world that remain underutilized in the United States.     One such therapy is mistletoe extract, a plant-based treatment that has been shown to support immune function and improve quality of life in cancer patients.      So on today's Cabral Concept 3315, I want to dive into the latest research on mistletoe therapy, its potential benefits, and what the science really says about its role in integrative cancer care. Enjoy the show, and let me know your thoughts!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3315 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!